The Asia Pacific Antacids Market should witness market growth of 3.9% CAGR during the forecast period (2023-2029).
Gastroenterologists and general practitioners face a special problem when treating the elderly population because of acid issues. Additionally, esophageal cancer and Barrett's esophagus are common symptoms in these patients. Antacid use in such circumstances has expanded dramatically. Such illnesses are treated with a combination of therapies, and this trend is expected to continue. The need for antacids is also being driven by e-commerce, which is causing a sharp increase in the number of online retail outlets. As a result, the rise in e-commerce and the number of online medical professionals are helping to fuel the market's expansion.
The only antacid forms previously accessible were pills, liquids, and powders. However, researchers have recently created a mouth-melting antacid that is made of microgranule that melt quickly in the mouth. Utilizing cutting-edge melting technology, these granules combine the therapeutic properties of herbal ingredients. As a result, an emerging trend in the antacid market known as mouth-watering antacids is anticipated to offer an attractive possibility for market expansion throughout the forecast period.
In 2005-2006, 13% of women and 9% of males between 15 and 49 ages were overweight or obese, according to the National Family Health Survey India-3 (NFHS-3). The prevalence of obesity was higher in urban areas in comparison to rural areas and was lower among individuals who worked in manual or agricultural activities. Overeating is the main factor that contributes to obesity. When food intake outpaces energy use, the body begins to store fat, which leads to obesity. Over time, overweight and obese people develop from consuming more calories than they can burn. One of the main reasons why people get obese is a change in lifestyle. Therefore, the market will experience significant growth in the region.
The China market dominated the Asia Pacific Antacids Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $622.4 Million by 2029. The Japan market is estimated to grow a CAGR of 3.3% during (2023-2029). Additionally, The India market would experience a CAGR of 4.5% during (2023-2029).
Based on Formulation Type, the market is segmented into Tablets, Liquids and Others. Based on Mechanism of Action, the market is segmented into Non-systemic and Systemic. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Alkem Laboratories Ltd., Bayer AG, Cipla Limited, Pfizer, Inc., Prestige Consumer Healthcare, Inc., Reckitt Benckiser Group PLC, WellSpring Pharmaceutical Corporation (Avista Capital Partners), Sanofi S.A. and Sun Pharmaceutical Industries Ltd.
Gastroenterologists and general practitioners face a special problem when treating the elderly population because of acid issues. Additionally, esophageal cancer and Barrett's esophagus are common symptoms in these patients. Antacid use in such circumstances has expanded dramatically. Such illnesses are treated with a combination of therapies, and this trend is expected to continue. The need for antacids is also being driven by e-commerce, which is causing a sharp increase in the number of online retail outlets. As a result, the rise in e-commerce and the number of online medical professionals are helping to fuel the market's expansion.
The only antacid forms previously accessible were pills, liquids, and powders. However, researchers have recently created a mouth-melting antacid that is made of microgranule that melt quickly in the mouth. Utilizing cutting-edge melting technology, these granules combine the therapeutic properties of herbal ingredients. As a result, an emerging trend in the antacid market known as mouth-watering antacids is anticipated to offer an attractive possibility for market expansion throughout the forecast period.
In 2005-2006, 13% of women and 9% of males between 15 and 49 ages were overweight or obese, according to the National Family Health Survey India-3 (NFHS-3). The prevalence of obesity was higher in urban areas in comparison to rural areas and was lower among individuals who worked in manual or agricultural activities. Overeating is the main factor that contributes to obesity. When food intake outpaces energy use, the body begins to store fat, which leads to obesity. Over time, overweight and obese people develop from consuming more calories than they can burn. One of the main reasons why people get obese is a change in lifestyle. Therefore, the market will experience significant growth in the region.
The China market dominated the Asia Pacific Antacids Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $622.4 Million by 2029. The Japan market is estimated to grow a CAGR of 3.3% during (2023-2029). Additionally, The India market would experience a CAGR of 4.5% during (2023-2029).
Based on Formulation Type, the market is segmented into Tablets, Liquids and Others. Based on Mechanism of Action, the market is segmented into Non-systemic and Systemic. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Alkem Laboratories Ltd., Bayer AG, Cipla Limited, Pfizer, Inc., Prestige Consumer Healthcare, Inc., Reckitt Benckiser Group PLC, WellSpring Pharmaceutical Corporation (Avista Capital Partners), Sanofi S.A. and Sun Pharmaceutical Industries Ltd.
Scope of the Study
By Formulation Type
- Tablets
- Liquids
- Others
By Mechanism of Action
- Non-systemic
- Systemic
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Alkem Laboratories Ltd.
- Bayer AG
- Cipla Limited
- Pfizer, Inc.
- Prestige Consumer Healthcare, Inc.
- Reckitt Benckiser Group PLC
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Antacids Market by Formulation Type
Chapter 4. Asia Pacific Antacids Market by Mechanism of Action
Chapter 5. Asia Pacific Antacids Market by Distribution Channel
Chapter 6. Asia Pacific Antacids Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Alkem Laboratories Ltd.
- Bayer AG
- Cipla Limited
- Pfizer, Inc.
- Prestige Consumer Healthcare, Inc.
- Reckitt Benckiser Group PLC
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
